secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092830
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone
--------------------------------------------------------------------------

- Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.
- Cash and investments $646.3M at June 30, 2024, up from $344.0M at Dec 31, 2023.
- R&D expense flat at $14.9M; G&A expense $7.8M vs $6.9M in prior year.
- Enrollment ongoing for JANX007 (PSMA) and JANX008 (EGFR) trials; JANX007 data update expected 2H 2024.
- Appointed Eric Dobmeier and Natasha Hernday to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024092830/0000950170-24-092830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024092830/janx-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer